Tevogen reports scientific, operational milestones achieved in 2025

Tevogen (TVGN) reported significant scientific and operational milestones achieved in 2025 within its biotechnology operations, reflecting Tevogen’s continued execution toward a scalable, established, multi-program cell therapy development organization. In 2025, Tevogen advanced its proprietary ExacTcell platform, expanded its cytotoxic T lymphocyte pipeline across multiple viral and oncology indications, and advanced its strategy to establish in-house GMP cell therapy manufacturing capabilities. Tevogen reported enhancements to ExacTcell that increased laboratory yields of target-specific CTLs per product, supporting improved consistency and throughput. Building on its SARS-CoV-2 proof-of-concept clinical experience, Tevogen completed T cell target identification for five additional HLA restrictions, significantly expanding potential patient coverage for its SARS-CoV-2-specific CTL product. Tevogen also advanced target discovery and preclinical activities supporting CTL therapies addressing: Epstein-Barr virus associated lymphomas; Chronic hepatitis B, including programs focused on prevention of virus-associated hepatic diseases and cancer; Human Papilloma Virus related cancers.